A 60 yr-old lady Underwent Successful Laparoscopic Surgery for Achalasia Crardia

S Singh
S Singh
· 2 min read
Achalasia Crardia is very rare with ratio of 1/ 100000

She was sleeping everyday at 45 degree angle to avoid reflux and sometimes on chair in sitting position. A Team of Gastroenterologist led by Dr Roy Patankar, Director & Gastroenterologist Zen Multi specialty Hospital successfully performed a laparoscopic surgery on 60 year old patient from Pune, Mrs. Sant who had complaints of mucus refluxing back in mouth with food moving very slowly through food pipe.

Achalasia Crardia is very rare with ratio of 1/ 100000

Mrs Sant, working professionally as special educator at Pune, was seen by local surgeon at Pune with complaints of food and mucus refluxing back in mouth with food moving very slowly through food pipe (As she describes). She was not able to lye down at all. She was sleeping everyday at 45 degree angle to avoid reflux, sometimes sleeping on chair in sitting position. Initially she was misdiagnosed as acidity. No relief with any medication at all.

She was referred to Dr Roy Patankar, Zen hospital and after consulting she underwent thorough work up. She underwent Endoscopy, Manometry (Measuring pressure in food pipe and Barium FT). She was diagnosed with Achalasia Cardia.

After confirming the diagnosis, Dr Roy Patankar suggested laparoscopic surgery in which pressure was released which avoid stoppage of food in food pipe and reflux to mouth. Post surgery she was completely relieved of symptoms and also was able to lye down in supine position (After many years). After surgery Mrs Sant was able to eat everything.

Dr Roy Patankar, Director & Gastroenterologist Zen Multi specialty Hospital, says, “Diagnosis is achieved by doing Barium x ray of esophagus (Special dye is given to patient to swallow and x ray is done) and endoscopy. After x ray, pressure of food pipe is measured by doing a test called manometry.”

“The esophageal motility disorder is where muscles of esophagus are not able to move food down through esophagus. Usually people complaints of difficulty in swallowing, regurgitation and sometimes chest pain.” says Dr Patankar.

Mrs Sant says “It was very difficult to stay sleepless and continuous refluxing food and mucus in outh. I m really happy post treatment I am able to sleep and back to work regularly.”

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk